ARTICLE | Clinical News
Twin Phase IIIs look good for Intarcia
October 3, 2014 3:06 AM UTC
Intarcia Therapeutics Inc. (Boston, Mass.) said ITCA 650 met all primary and secondary endpoints in two Phase III trials to treat Type II diabetes.
ITCA 650 provides patients continuous subcutaneous delivery of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, via an implantable osmotic pump. ...